STEALTH® liposomal CKD-602, a topoisomerase I inhibitor, improves the therapeutic index in human tumor xenograft models

Anticancer Research

Volumn 27, Issue 4 B, 2007, Pages 2541-2545

  Yu, Ning Y ^a   Conway, Colleen ^a   Pena, Rhoneil L S ^a   Chen, Joy Y ^a  

^a ALZA CORPORATION   (United States)

Author keywords

Camptothecin; Human tumor xenografts; S CKD602; STEALTH liposomes; Therapeutic index; Topotecan

Indexed keywords

BELOTECAN; LIPOSOMAL BELOTECAN; TOPOTECAN; UNCLASSIFIED DRUG; 7 (2 (N ISOPROPYLAMINO)ETHYL)CAMPTOTHECIN; 7-(2-(N-ISOPROPYLAMINO)ETHYL)CAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DRUG DERIVATIVE; ENZYME INHIBITOR; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; MELANOMA; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; CELL STRAIN HT29; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG SCREENING; ENZYMOLOGY; HUMAN; LUNG TUMOR; NEOPLASM; SMALL CELL CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, SMALL CELL; DNA TOPOISOMERASES, TYPE II; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HT29 CELLS; HUMANS; LIPOSOMES; LUNG NEOPLASMS; MELANOMA; MICE; MICE, NUDE; NEOPLASMS; TOPOTECAN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34547741657     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Jew SS, Kim MG, Kim HJ, Roh EY, Park HG, Kim JK, Han HJ and Lee H: Synthesis and in vitro cytotoxicity of C(20)(RS)-camptothecin analogues modified at both B (or A) and E ring. Bioorg Med Chem Lett 8: 1797-18002, 1998.
2. Lee J-H, Lee J-M, Kim J-K, Ahn S-K, Lee S-J, Kim M-Y, Jew S-S, Park J-G and Hong CIL: Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)- camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch Pharm Res 21(5): 581-590, 1998.
3. Crul M: CKD-602. Chong Kun Dang. Curr Opin Investig Drugs 4(12): 1455-1459, 2003.
4. Dvorak HF, Nagy JA, Dvorak JT and Dvorak AM: Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 133(1): 95-109, 1988.
5. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D and Jain RK: Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 54(13): 3352-3356, 1994.
6. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP and Jain RK: Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 55(17): 3752-3756, 1995.
7. Houghton PJ, Cheshire PJ, Hallman JD II, Lutz L, Friedman HS, Dands MK and Houghton JA: Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36: 393-403, 1995.
8. Morris R and Munkarah A: Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer. The Oncologist 7(s5): 29-35, 2002.
9. Santana VM, Zamboni WC, Kirstein MN, Tan M, Liu T, Gajjar A, Houghton PJ and Stewart CF: A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res 9: 633-640, 2003.
10. Armstrong DK: Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity. The Oncologist 9: 33-42, 2004.
11. Eckardt JR: Emerging role of weekly topotecan in recurrent small cell lung cancer. The Oncologist 9(s6): 25-32, 2004.
12. Wagner S, Erdlenbruch B, Langler A, Gnekow A, Kuhl J, Albani M, Volpel S, Bucsky P, Emser A, Peters O and Wolff J: Oral topotecan in children with recurrent or progressive high-grade glioma. Cancer 100(6): 1750-1757, 2004.